This site would like to set some non-essential temporary cookies. Some cookies we use are essential to make our site work.
Others such as Google Analytics help us to improve the site or provide additional but non-essential features to you.
No behavioural or tracking cookies are used.
To change your consent settings, read about the cookies we set and your privacy, please see our Privacy Policy
Back to Contents
Volume: 12 Issue: 2
( 2012)
Keywords:
reverse
payment
agreement
between
generic
drugs
manufacturer
having
filed
paragraph
iv
certification
produce
generic
form
patented
drug
pioneer
manufacturer
Jurisdictions:
US
PATENTS: A reverse payment agreement between a generic drugs manufacturer having filed a paragraph IV certification to produce a generic form of a patented drug, with the pioneer manufacturer, does not violate U.S. antitrust laws.
Federal Trade Commission v Watson Pharmaceuticals, Inc.
No. 10-12729 (11th Cir. Apr. 25, 2012)
A reverse payment agreement between a generic drugs manufacturer having filed a paragraph IV certification to produce a generic form of a patented drug, with the pioneer manufacturer, does not violate U.S. antitrust laws.
You must be logged in and have an active full subscription to view full articles. Log in now
Comments
You must be logged in and have an active full subscription to view and post comments. Log in now
Social Media
